NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Accrued Expenses and Other Current Liabilities

6 Months Ended

Mar. 31, 2022

6. Accrued Expenses and Other Current Liabilities

The Company’s accrued expenses and other current liabilities consisted of the following:


	As of March 31,		As of September 30,
	2022		2021
Accrued compensation and benefits	$	1,060,905	$	880,707
Accrued consulting settlement		400,000		200,000
Accrued professional fees		78,277		299,557
Accrued research and development		881,981		297,047
Accrued franchise tax		247,092		30,720
Other accrued expenses		34,132		39,715
Total	$	2,702,387	$	1,747,746